Shots:
- The EC has approved Abrysvo to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals (aged 18-59yrs.) across all EU states including Iceland, Liechtenstein, and Norway.
- Approval was based on a pivotal P-III (MONeT) study that assesses the safety, tolerability & immunogenicity of Abrysvo vs PBO in adults (aged 18-59yrs.) at risk of RSV-associated LRTD due to certain chronic conditions. These findings were supported by thousands vaccinated by ABRYSVO across multiple trials including MONeT, with results published in peer-reviewed journals.
- ABRYSVO is an unadjuvanted, bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine designed to protect against RSV-LRTD, regardless of virus subgroup
Ref: Businesswire | Image: Pfizer
Related News:- Genmab and Pfizer Secure the EC’s Approval for Tivdak (Tisotumab Vedotin) for Recurrent or Metastatic Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
